Core Insights - Longevity Health Holdings, Inc. (XAGE) focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [2] - The company announced a merger agreement with 20/20 BioLabs, which will continue as a wholly owned subsidiary post-merger [4] Business Updates - 20/20 develops laboratory tests for early detection and management of chronic disease risk, including a multi-cancer early detection blood test and a new blood test for monitoring chronic inflammation [1][4] - XAGE reported Q1 sales of approximately $663,000, an 8% increase year-over-year, while 20/20 reported sales of approximately $562,000, a 15% increase year-over-year [4] - A reverse stock split of 1 for 30 was completed on May 12, 2025, with trading at the adjusted price starting on May 14, 2025 [4] Product Launches - XAGE plans to launch a medicated cleanser for use in physicians' offices and MedSpas, targeting 20/20's customer base [4] - 20/20 is set to launch a lab test measuring inflammatory biomarkers, which will also be marketed to XAGE's customer base [4] - An initiative with Giant Food will offer 20/20's multi-cancer test in select stores, with potential expansion to include tests for biomarkers linked to pro-inflammatory foods [4] Financial Considerations - XAGE is evaluating options for additional financing and anticipates announcing a primary investment in Q2 2025 [4]

Core Viewpoint - Longevity Health Holdings, Inc. has announced a merger with 20/20 BioLabs, Inc. in an all-stock transaction aimed at enhancing its diagnostics capabilities and addressing chronic disease risks in America [1][4]. Company Overview - Longevity Health Holdings focuses on human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][10]. - 20/20 BioLabs specializes in laboratory tests for early detection and management of chronic disease risk, offering the only multi-cancer early detection blood test available for under $200 [9][10]. Merger Details - The merger is expected to close in the third quarter of 2025, pending customary closing conditions and stockholder approvals [7]. - Post-merger, 20/20 stockholders will own approximately 50.1% and Longevity stockholders will own approximately 49.9% of the combined company [7]. - The combined company will continue trading on Nasdaq under the symbol "XAGE" [1]. Financial Implications - The merger is projected to double Longevity's fiscal year 2025 revenue forecast from approximately $3-4 million to approximately $7-8 million [6][7]. - The combined company is expected to have a post-merger equity valuation of approximately $99 million, with 20/20's pre-money valuation at around $50 million [6][7]. - Anticipated operational savings and synergies are expected to exceed $1 million in fiscal year 2025 [6]. Strategic Goals - The merger aligns with Longevity's strategy to expand its footprint in diagnostics and enhance synergies with its existing product portfolio [1][4]. - The combined company aims to address the epidemic of chronic disease in America under the "Healthy Aging, Inside and Out™" initiative [1]. Management Structure - The management team of the combined company will be mutually selected, with a Board of Directors comprising three members from each company [8].